



# LUNG-MAP

A lung cancer precision medicine trial

## Even in Difficult Times, Lung-MAP is Going Strong

**Despite the coronavirus pandemic** and its strain on cancer centers and hospitals, our precision medicine trial continues to benefit patients diagnosed with non-small cell lung cancer

- Even with a dip in late March, trial accrual is keeping pace with study averages
- Lung-MAP partner Foundation Medicine, Inc. continues to process study samples
- The pipeline for new drugs continues to increase, with one sub-study expected for activation by the end of 2020. Additional sub-studies are currently being developed for activation in 2021

**Since Lung-MAP expanded in January 2019**, the trial has averaged 86 patients per month registering to be screened each month.

As of May 12, 2020, we've had:

- Screening registrations: **1,216**
- Sub-Study assignments: **591**
- Sub-Study registrations: **165**

**This progress is due to you! Thanks to the research staff at all of our 700 participating Lung-MAP sites. Together, we are making a real difference for people with lung cancer.**

### TOP ACCRUING SITES

1. University of Pittsburgh Cancer Institute, Pittsburgh, PA	59
2. Missouri Baptist Medical Center, St. Louis, MO	24
3. Mercy Medical Center, Baltimore, MD	22
4. University of Oklahoma Health Sciences Center, Oklahoma City, OK	21
5. University of Rochester, Rochester, NY	20
6. University of New Mexico Comprehensive Cancer Center, Albuquerque, NM	19
7. Northside Hospital, Atlanta, GA	18
7. University of Kentucky Markey Cancer Center, Lexington, KY	18
8. Northwestern Memorial Hospital, Chicago, IL	17
8. Essentia Health Cancer Center, Duluth, MN	17
9. Mercy Hospital St. Louis, St. Louis, MO	16
10. Roswell Park Comprehensive Cancer Institute, Buffalo, NY	15
10. Good Samaritan Hospital, Cincinnati, OH	15

*data reflects trial activity as of 5/12/2020*

LEARN MORE AT  
[WWW.LUNG-MAP.ORG](http://WWW.LUNG-MAP.ORG)



## Active Sub-Studies:

**1. S1800A “A Phase II/III Randomized Study of Pembrolizumab Plus Ramucirumab Versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer”**

**Accrual goal:** 144

**Primary Objective:** To compare overall survival between patients previously treated with platinum-based chemotherapy and immunotherapy for Stage IV or recurrent non-small lung cancer randomized to ramucirumab and MK-3475 (pembrolizumab) versus standard of care.

**2. S1900A “A Phase II Study of Rucaparib in Patients with LOH+Positive STAGE IV Non-small Lung Cancer”**

**Accrual goal:** 88

**Primary Objective:** Evaluate the response rate associated with rucaparib in patients with genomic loss of heterozygosity high and/or deleterious BRCA 1/2 mutation-positive non-small cell lung cancer. A biomarker-driven study for patients with Stage IV or recurrent non-small cell lung cancer.

*Note: Only cohort 1 (squamous) is open to accrual at this time. Cohort 2 (nonsquamous) is temporarily closed to let data mature for analysis.*

**3. S1900B “A Phase II Study of LOXO-292 in Patients with RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer”**

**Accrual goal:** 124

**Primary Objective:** Evaluate the response rate to LOXO-292 – a novel, highly selective, ATP-competitive small molecule RET inhibitor – in patients with previously-treated stage IV or recurrent RET fusion-positive non-small cell lung cancer.

*Note: Because RET fusions are very rare, this sub-study allows patients with documentation of RET fusions detected from outside of Lung-MAP to use these results to participate in S1900B.*

**4. S1900C “A Phase II Study of Talazoparib Plus Avelumab In Patients with Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations”**

**Accrual goal:** 44

**Primary Objective:** Evaluate the response rate with the PARP inhibitor talazoparib plus the monoclonal antibody avelumab in patients with Stage IV or recurrent, non-squamous non-small cell lung cancer bearing pathogenic STK11 genomic alterations who were previously treated with anti-PD-1/PD-L1 therapy and platinum-based chemotherapy.

## Lung-MAP featured in the ASCO20 Virtual Scientific Program

Lung-MAP study co-chair Mary Redman, PhD, will present a Lung-MAP poster as part of the 2020 online annual meeting of the American Society of Clinical Oncology (ASCO), which runs May 29-31. The poster — titled “Lung-MAP (SWOG S1400): Design, implementation, and lessons learned from a biomarker-driven master protocol for previously-treated squamous lung cancer” — summarizes the first screening study in our precision medicine trial. View Redman’s research [here](#).



### CONTACT US

**Protocol & Regulatory Questions**  
[lgildner@swog.org](mailto:lgildner@swog.org) or [mnorman@swog.org](mailto:mnorman@swog.org)

**Eligibility & Data Submission Questions**  
[LUNGMAPQuestion@crab.org](mailto:LUNGMAPQuestion@crab.org)

**General Medical Questions**  
[LUNGMAP@swog.org](mailto:LUNGMAP@swog.org)

**S1900A Medical Questions**  
[S1900AMedicalQuery@swog.org](mailto:S1900AMedicalQuery@swog.org)

**S1800A Medical Questions**  
[S1800AMedicalQuery@swog.org](mailto:S1800AMedicalQuery@swog.org)

**S1400F Medical Questions**  
[S1400FMedicalQuery@swog.org](mailto:S1400FMedicalQuery@swog.org)

**Central Monitoring Questions**  
[centralmonitorquestion@crab.org](mailto:centralmonitorquestion@crab.org)

**Quality Assurance Auditing Questions**  
[qamail@swog.org](mailto:qamail@swog.org)

**Funding Questions**  
[funding@swog.org](mailto:funding@swog.org)